BioWa, Inc., a New Jersey-based biotech company, and a wholly owned subsidiary of Kyowa Kirin Co, Ltd., was incorporated in Delaware in 2003. BioWa has been committed to improving health through advancements in life science and technology. BioWa's mission is the out-licensing of Kyowa Kirin's Therapeutic Antibody Technologies, POTELLIGENT^® and COMPLEGENT^® . Even our company name, BioWa, reflects our commitment. It suggests the synergistic combination of American and Japanese sensibility. "Bio", from the West, means "life" (as biology is the study of life) and "Wa", from the East, is most often associated with "heart" and "harmony". Together, the name BioWa reflects an earnest objective to improve the quality of life for all.

Therapeutic Antibody Technologies Out-Licensing
BioWa is the exclusive worldwide licensor of POTELLIGENT^® Technology, a proprietary technology that creates 100% fucose-free monoclonal antibodies – antibodies that demonstrate a marked increase in antibody-dependent cellular cytotoxicity (ADCC). A critical function of the immune system, ADCC enhances the ability of antibodies to kill tumor cells. With BioWa's technology, enhancement of monoclonal antibody (MAb) potency has been shown to increase up to 100 fold both in vitro and in vivo. BioWa is also the worldwide exclusive licensor of COMPLEGENT^®, a proprietary, robust technology to enhance complement-dependent cytotoxicity (CDC) of therapeutic antibodies. COMPLEGENT^® Technology may be used with POTELLIGENT^® Technology, providing AcrretaMab^® platform, a new class of antibodies to fight cancers and other life-threatening diseases.

Facts and Highlights